Effect of a Passive Endocardial Electrode on Defibrillation Efficacy of a Nonthoracotomy Lead System  by Fotuhi, Parwis C et al.
Effect of a Passive Endocardial Electrode on Defibrillation Efficacy of
a Nonthoracotomy Lead System
PARWIS C. FOTUHI, MD, BRUCE H. KENKNIGHT, MS,* SHARON B. MELNICK, AS,†
WILLIAM M. SMITH, PHD,† GERT F. BAUMANN, MD, RAYMOND E. IDEKER, MD, PHD†
Berlin, Germany; St. Paul, Minnesota; and Birmingham, Alabama
Objectives. We investigated the impact of an inactive endocar-
dial lead on the 50% effective dose (ED50%) for successful
ventricular defibrillation.
Background. The presence of abandoned epicardial mesh patch
electrodes detrimentally affects the defibrillation efficacy of an
endocardial lead system. It is not known whether abandoned
endocardial electrodes produce a similar effect.
Methods. An endocardial lead system (ENDOTAK, model 0062,
Cardiac Pacemakers, Inc.) was implanted in eight dogs (mean
6SD weight 23.7 6 1.0 kg). The ED50% for each of seven lead
configurations was determined by a three-reversal point protocol
in a balanced-randomized order with and without a second
electrically passive endocardial lead system in the right ventricle
(power 0.97 to detect a 50-V difference). Biphasic shocks with 80%
tilt were delivered 10 s after the induction of ventricular fibrilla-
tion. In one configuration the active electrode made contact with
the passive electrode in the right ventricular (RV) apex. In
another configuration the active electrode was placed in a more
proximal position to avoid contact. Additionally, the ED50% was
determined for the endocardial lead system with a passive pacing
lead positioned in the RV apex.
Results. ED50% values for peak voltage, peak current and
delivered energy were not significantly different with or without a
passive RV electrode, and this was true whether or not the active
electrode touched the passive electrode. However, ED50% values
were significantly higher when the active electrode was slightly
proximal than when it was positioned at the apex.
Conclusions. Physical contact between active and passive endo-
cardial electrodes does not significantly alter defibrillation effi-
cacy in this dog model. An increase in ED50% energy was caused
by a slightly proximal position. Therefore, a good electrode
position within the right ventricle is a more important determi-
nant of defibrillation efficacy than is avoidance of the electrode
touching a passive electrode.
(J Am Coll Cardiol 1997;29:825–30)
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Since the first implantation of an internal defibrillator 15 years
ago (1), major changes and achievements have been made in
this form of treatment for life-threatening ventricular arrhyth-
mias (2,3). First-generation devices primarily used epicardial
lead systems. Today, implantable cardioverter-defibrillator
(ICD) devices utilize endocardial-based lead systems almost
exclusively (4,5).
The nearly universal use of endocardial-based lead systems
for first-time ICD implantation has created a dilemma for
electrophysiologists and surgeons: When replacing early-
model ICD pulse generators after battery depletion, or in the
rare cases where epicardial lead systems have malfunctioned,
should the epicardial leads be abandoned in favor of a new
endocardial lead system? The results from two recent short-
term animal studies (6,7) suggest that the presence of aban-
doned (electrically passive) epicardial electrodes significantly
increases defibrillation energy requirements. A similar ques-
tion needs to be answered for endocardial defibrillation lead
systems as well. When endocardial defibrillation leads mal-
function (8,9), should the old lead be abandoned without
attempting extraction as pacing leads are often treated? (10).
Epstein et al. (11) showed the presence of fibrous connective
tissue and endocardial fibrosis around a transvenous electrode
system. Therefore, defibrillation lead extraction may be con-
traindicated due to medical risk and procedural morbidity. In
such cases, endocardial lead abandonment might be favored.
However, the impact of an abandoned endocardial lead system
on defibrillation efficacy has not been investigated systemati-
cally. Therefore, the purpose of the present study was to
evaluate the impact of a passive endocardial defibrillation lead
on the defibrillation energy requirements of an active endo-
cardial defibrillation system. We also examined the impact of a
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conventional pacing lead on the active endocardial defibrilla-
tion configuration.
Methods
The study was approved by the Institutional Animal Care
and Use Committee at the University of Alabama at Birming-
ham. It conforms to the “Guidelines of the American Heart
Association on Research Animal Use” adopted November 11,
1984.
Animal preparation. In eight mongrel dogs (mean6 SD
weight 23.76 1.0 kg), anesthesia was induced with intravenous
pentobarbitol (30 to 35 mg/kg body weight) and maintained
with a continuous infusion of pentobarbitol at a rate of
;0.05 mg/kg per min (12,13). Succinylcholine (1 mg/kg) was
also given intravenously at the time of induction of anesthesia.
Supplemental doses of succinylcholine (0.25 to 0.5 mg/kg) were
given as needed to maintain muscle relaxation. The animals
were intubated with a cuffed endotracheal tube and ventilated
with room air and oxygen through a Harvard respirator
(Harvard Apparatus Co.). A peripheral intravenous line was
inserted, and normal saline was continuously infused. A fem-
oral artery line was placed for hemodynamic monitoring as
well as for arterial blood gas analysis and electrolyte measure-
ments. Normal metabolic status was maintained throughout
the study by taking blood samples every 30 to 60 min and
correcting any abnormal values. Electrocardiographic (ECG)
electrodes were applied for continuous monitoring of lead II.
Body temperature was measured through an esophageal tem-
perature probe and maintained at 36 to 388C with a thermal
mattress and heat lamp. At the end of the study, euthanasia
was induced with a potassium chloride injection. The heart was
removed and weighed.
Defibrillation lead configuration. One 11F defibrillation
catheter (ENDOTAK, model 0062, Cardiac Pacemakers, Inc.)
with a distal 3.4-cm right ventricular (RV) coil electrode, a
6.8-cm superior vena cava (SVC) coil electrode 9 cm proximal
from the distal coil and a pacing electrode tip 6 mm distal from
the RV coil was placed through a right jugular vein incision.
Under fluoroscopic guidance, the distal coil was advanced in
the RV apex, and the proximal coil was positioned in the SVC
to serve as the anode for the first phase of the biphasic shock.
A second, identical defibrillation catheter was placed through
a left jugular vein incision to serve as a passive “bystander” in
configurations 2 and 5 (described later).
Figure 1 shows a diagrammatic representation of the lead
type (active or passive) and the approximate distal electrode
position within the canine heart for the seven lead configura-
tions that were tested. Each configuration was tested sepa-
rately within each animal. The first three configurations were
used to investigate whether a passive electrode in contact with
the RV catheter electrode alters defibrillation efficacy. Config-
uration 1 consists of the active electrode in the RV apex with
the passive electrode not present. Configuration 2 consists of
the new, active electrode and the passive electrode in contact
with it, mimicking the clinical scenario, where a new endocar-
dial lead is implanted without removing the inactive old lead.
In configuration 3, the passive electrode from configuration 2
has been removed. Configurations 4, 5 and 6 were used in a
similar manner to determine whether a passive electrode
affects defibrillation efficacy if it is present in the right ventricle
but not in contact with the active electrode. Configuration 4
consists of the active electrode alone. Configuration 5 consists
of a passive electrode positioned in the RV apex and an active
electrode not touching it. The passive electrode was the same
electrode that was active in configuration 4. Configuration 5 is
intended to simulate the clinical scenario where an electrode
that was placed in the normal position is now not functioning,
and a new electrode has to be placed. To avoid physical contact
between the apical passive lead and the new active lead, the
active lead was placed in a more proximal position. In config-
uration 6, the passive electrode from configuration 5 has been
removed. A seventh configuration was studied to investigate
whether the presence of a conventional pacing lead (Irox tip,
bipolar lead, 58-cm length, Intermedics, Inc.) near the distal
electrode (floating electrode) of the defibrillation lead influ-
ences the effective dose for successful ventricular defibrillation
(ED50%). The locations of the electrodes for each configura-
tion were confirmed fluoroscopically.
Defibrillation protocol and data acquisition. The order in
which each lead configuration was tested was defined by a
block randomization scheme. On the basis of this randomiza-
tion, group 1 (configurations 1 to 3) or group 2 (configurations
4 to 6) was tested first. Configuration 7 was tested randomly
after configuration 3 or 6. ED50% testing was performed by
following a modified three-reversal up–down protocol (13,14)
starting with a leading edge voltage of 400 V. The initial step
size was 40 V. If the first shock failed, incremental 40-V shocks
were given until a defibrillation success occurred (first rever-
sal). After a defibrillation success, the voltage was decreased by
40-V steps until the shock failed to defibrillate (second rever-
sal). Then, the voltage was increased again by 40-V steps until
a successful defibrillation occurred (third reversal). If the first
shock succeeded, decremental 40-V shocks were performed
until the shock failed (first reversal). After a failure, the voltage
was increased by 40-V steps until the shock succeeded (second
reversal). Then, the voltage was decreased again by 40-V steps
until a failure occurred (third reversal). The ED50% for peak
voltage was defined as the mean peak voltage of the three
reversal points. Similarly, the ED50% for delivered energy and
peak current was found by averaging the energy and peak
current values for these three shocks.
Ventricular fibrillation was induced by 60-Hz alternating
Abbreviation and Acronyms
ECG 5 electrocardiogram, electrocardiographic
ED50% 5 effective dose for successful ventricular defibrillation
ICD 5 implantable cardioverter-defibrillator
RV 5 right ventricular
SVC 5 superior vena cava
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current through the pacing tip of the RV apex defibrillation
lead, with the return electrode on the chest wall. Fibrillation
was allowed to continue for 10 s before defibrillation was
attempted. A failed shock was followed by a rescue shock of
higher voltage delivered between the internal electrodes. If the
first rescue shock failed, it was followed by external defibrilla-
tion with a Life-Pak 9 defibrillator (Physio-Control Corp.),
given through the external defibrillator patches. A minimum of
4 min elapsed between each fibrillation–defibrillation attempt.
Fibrillation was not reinitiated until blood pressure and heart
rate had returned to normal.
The defibrillation electrodes were connected to a defibrillator
(VENTAK, model 2805, Cardiac Pacemakers, Inc.). This defibril-
lator, modified for research, delivered a fixed-tilt (80%) single-
capacitor biphasic shock from a 125-mF capacitor bank. The
leading edge voltage and the tilt of the first phase were program-
mable. The truncated exponential biphasic shock utilized a sec-
ond phase of opposite polarity to the first phase, with the
second-phase leading edge voltage equal to 100% of the first-
phase trailing edge voltage. The total duration depended on the
impedance and ranged from 15.4 to 20.5 ms. The second phase
duration was always 40% of the total duration. The current and
voltage waveforms delivered to the animal were digitized at 20
kHz and recorded by a waveform analyzer (Data Precision 6100).
Signal analysis software within the analyzer was used to obtain
impedance and energy measurements. The data were transferred
to a Macintosh computer for statistical analysis.
Statistical analysis. Results are expressed as the mean
value 6 SD of the ED50% for delivered energy, peak voltage,
peak current and impedance for each configuration. Analysis
of variance was adjusted for repeated measurements and was
performed for the different configurations (SPSS, version 5.02,
SPSS, Inc. and ISP version 3.3, Datavision AG, Switzerland).
Statistical significance was defined as p # 0.05. The power of
the study was 0.97, and 50-V difference was considered mean-
ingful.
Figure 1. Defibrillation electrode con-
figurations tested: an active RV defibril-
lation lead alone in the apex (configu-
rations 1 and 4, active lead); an active
apical defibrillation lead (configuration
2, active lead) in contact with a passive
defibrillation lead (configuration 2, pas-
sive lead) in the apex; the newly placed
active defibrillation lead alone in the
apex (configuration 3, active lead); a
passive defibrillation lead in the apex
(configuration 5, passive lead) with an
active lead with the tip proximal to the
passive lead (configuration 5, active
lead); an active lead alone at the prox-
imal position (configuration 6, active
lead); and an active defibrillation lead
(configuration 7, active lead) in combi-
nation with a conventional pacing elec-
trode (configuration 7, pacing lead).
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Results
Figure 2 shows a bar graph for ED50% energy. There were
no significant differences for peak voltage, peak current,
energy delivered or impedance among configurations 1, 3 and
4. To isolate the impact of the passive lead, the ED50% values
associated with configurations 1, 3 and 4 were compared with
those for configurations 2, 5 and 6. No significant differences
were found between configuration 2 and configuration 1, 3 or
4.
In contrast to configuration 2, in which the passive elec-
trode was in contact with the active electrode in the RV apex,
configuration 5, in which the active RV electrode was posi-
tioned proximal to the passive electrode, yielded different
results. When the active lead was proximal to the RV apex, the
ED50% was increased significantly, but impedance values were
not different. To determine whether the significant increase
was due to the lead position or to the passive lead, the passive
lead was removed, and the active lead position was unchanged
(configuration 6). There were no significant differences for
ED50% values detected for configuration 5 versus configura-
tion 6.
Impedance values are shown in Figure 3. The impedance
for configuration 2 was lowest but was statistically significantly
different from configuration 4 only.
In Table 1, the mean voltage of the three reversal points is
shown for all eight dogs individually, demonstrating the wide
range. No systematic reason was found to explain the increase
or decrease in each individual animal.
Discussion
Today, the majority of patients who need an implantable
defibrillator for the treatment of ventricular arrhythmias can
be treated with an endocardial-based ICD system (5,15). On
rare occasions, lead malfunction may necessitate implantation
of a new endocardial lead for defibrillation. To our knowledge,
no controlled study to determine the effect of “bystander”
endocardial leads on defibrillation efficacy has been reported.
Two previous studies (6,7) demonstrated that the presence of
epicardial patch electrodes dramatically increases the shock
strength required to defibrillate dogs using an endocardial-
based lead system. Therefore, it was important to determine
whether an electrically passive endocardial defibrillation lead
might similarly impact defibrillation efficacy by providing a
shunt path for the defibrillating current either when the
passive electrode was in contact with the active electrode or
when the active electrode was positioned at a slight distance
from the passive electrode to avoid contact with it. We
designed the present study to address both situations.
The major finding of this study is that the presence of an
electrically passive endocardial defibrillation lead having a
distal electrode either in contact with or not in contact with the
active RV electrode does not significantly alter defibrillation
efficacy. A possible explanation for this finding is that the
current shunting caused by the passive electrode affects an area
with a high potential gradient near the active electrode. The
current shunting would not be expected to lower this strong
gradient sufficiently to decrease it below the level needed to
defibrillate because it would be in an area where the potential
gradient is already weak. In fact, there was a nonsignificant
trend suggesting that ED50% values were lower when both
passive and active leads were present and their distal elec-
trodes were in contact in the RV apex (configuration 2). The
mechanism for this observed behavior may be related to the
shock impedance. The slightly lower impedance for configura-
tion 2 could have been caused by the larger effective surface
area when the passive and active electrodes were in contact.
Figure 2. Mean ED50% and standard deviation for energy of both
phases for all seven lead configurations. *p # 0.05, configurations 5
and 6 versus configurations 1 to 4 and 7.
Figure 3. Mean ED50% and standard deviation for impedance for all
seven lead configurations. *p # 0.05, configuration 2 versus configu-
ration 4.
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This lower impedance would allow a higher current to flow at
a given shock voltage.
By comparing the difference in ED50% between configu-
rations 2 and 3 and the difference between configurations 5 and
6, we were able to infer that the increase in ED50% for
configuration 5 compared with configuration 1 or 4 was due to
the position of the active RV electrode relative to the RV apex
and not to the presence of the passive electrode. The ED50%
increases as the distal tip of the RV electrode is drawn out of
the apex (16). The same holds true for the pacing lead. The
pacing lead does not affect the ED50% but might prevent good
placement of the defibrillation lead (17). Therefore, obtaining
a good position for the RV electrode in the RV apex is much
more important than attempting to place the RV electrode to
avoid an old passive defibrillation electrode.
Clinical implications. These findings have important clin-
ical implications because in the future it is likely that decisions
concerning endocardial defibrillation lead abandonment or
extraction will need to be made. The X ray images shown in
Figure 4 are from a patient with malfunctioning endocardial
leads that could not be removed due to fibrous tissue at the
superior cava/right atrial junction. On the basis of data from
this animal study, we abandoned the inactive electrode system
and implanted a second electrically active system, as shown in
Figure 4. According to the previous rationale, the second lead
was placed as far as possible into the right apex. In the present
canine study, we did not investigate whether the sensing
characteristics of the active lead were changed by the presence
of the passive defibrillation or pacing lead or the long-term
effect on mechanical integrity of implanted defibrillation leads
in contact with another. For this reason, any mechanical
contact of the two electrodes was avoided in this patient,
resulting in a fully functioning lead system, including a defi-
brillation threshold of 15 J. This scenario is not a general
recommendation for the abandonment of all leads, but in the
situation shown in Figure 4, abandoning inactive endocardial
electrodes is a possible alternative to cardiocthoracic surgical
removal. In these selected patients, careful intraoperative
testing is mandatory.
Conclusions. Within the limitations of a canine model, our
results suggest that defibrillation efficacy of endocardial lead
systems will not be detrimentally affected by the presence of a
passive “bystander” electrode in the right ventricle. However,
if the abandoned lead physically prevents the new lead from
being implanted with its distal tip in the RV apex, the
defibrillation strength requirements would be expected to
Figure 4. Anteroposterior (left) and lateral (right) X-ray views in a
patient with an abandoned and an active endocardial electrode system.
Table 1. Individual Defibrillation Thresholds
Dog 1 Dog 2 Dog 3 Dog 4 Dog 5 Dog 6 Dog 7 Dog 8
Conf. 1 524.8 6 76.6 464.8 6 84.4 493.2 6 26.1 385.6 6 44.1 361.0 6 88.6 476.1 6 65.8 297.9 6 43.2 348.6 6 24.1
Conf. 2 496.4 6 21.8 474.2 6 66.9 408.6 6 41.1 409.3 6 49.2 313.8 6 24.0 297.3 6 28.0 305.2 6 24.0 329.5 6 43.7
Conf. 3 403.3 6 24.8 521.7 6 63.8 444.1 6 24.3 423.9 6 43.7 345.6 6 45.2 404.6 6 49.6 254.6 6 42.0 349.0 6 23.7
Conf. 4 340.7 6 42.6 459.3 6 99.3 413.8 6 41.7 460.0 6 27.6 299.0 6 43.9 459.2 6 25.6 316.0 6 23.8 364.1 6 64.6
Conf. 5 571.7 6 22.5 618.9 6 23.5 688.3 6 23.8 402.5 6 23.9 354.6 6 25.4 671.6 6 22.1 379.8 6 41.9 440.2 6 20.8
Conf. 6 519.8 6 88.1 619.7 6 86.3 654.1 6 40.8 403.2 6 27.3 372.1 6 67.5 623.7 6 69.2 498.7 6 23.5 509.3 6 48.9
Conf. 7 319.2 6 49.6 394.8 6 22.5 409.8 6 41.0 394.0 6 25.7 370.8 6 65.2 432.5 6 46.3 374.0 6 49.1 379.4 6 62.5
Data presented are mean voltage 6 SD of the three reversal points in each dog for each lead configuration (Conf.)
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increase. On the basis of the present animal model data, the
important factor for the ED50% defibrillation requirements
when using an active endocardial-based system together with
an inactive endocardial lead system seems to be the lead
position. Although the presence of a passive endocardial
defibrillation lead did not detrimentally affect defibrillation
efficacy in the present study, these results alone are not
sufficient to recommend abandonment of defibrillation leads.
The decisions for implanting a second lead should include
careful and complete testing of sensing characteristics during
normal rhythms and during ventricular fibrillation to ensure
that the ICD system functions properly.
We thank Danielle Winkler for help with the preparation of the figures and
manuscript and Jeanette Bicknell, Robin Walker and Biyu Zheng for their
technical assistance.
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